# Developing monoclonal antibody therapies for measles could lead to adverse pathogen evolution

## TL;DR

Using monoclonal antibodies to treat measles could cause the virus to evolve in ways that weaken vaccine effectiveness.

## Contribution

The paper highlights the risk of monoclonal antibody therapies promoting adverse evolution in the measles virus.

## Key findings

- Monoclonal antibody therapies may drive measles virus evolution.
- Such evolution could undermine the protection provided by vaccination.

## Abstract

Monoclonal antibody therapies are being developed to treat measles in response to its recent resurgence. These therapies risk driving measles virus evolution in ways that might undermine the protection offered by vaccination, outweighing potential benefits.

Monoclonal antibody therapies are being developed to treat measles in response to its recent resurgence. This Perspective argues that such therapies risk driving measles virus evolution in ways that might undermine the protection offered by vaccination.